Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects with Psoriasis

The purpose of this study is to determine the effect of

etanercept 50 mg twice weekly compared to placebo over 12 weeks on the

psoriasis area and severity index (PASI) in subjects with psoriasis. This

study will also evaluate the safety and tolerability of etanercept 50 mg

twice weekly; determine the effect of etanercept 50 mg twice weekly on

patient reported outcomes (PRO); and characterize the pharmacokinetics (PK) profile of

etanercept 50 mg twice weekly.